| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 13 Feb 2026 | 23 Jan 2026 |
| Alkem Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2026 ,inter alia, to consider and approve (i) the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and nine months ended 31st December, 2025; and (ii) Interim Dividend for financial year 2025-2026. The record date for the purpose of payment of Interim Dividend for financial year 2025-2026, would be Friday, 20th February, 2026, subject to declaration of the said Interim Dividend by the Board of Directors in its meeting to be held on 13th February, 2026. Please find enclosed herewith the outcome of Board meeting dated 13th Feb, 2026. This is to inform you that the Board of Directors of the Company has at its meeting held on 13th February, 2026 approved the amalgamation of M/s. Adroit Biomed Limited, a wholly owned subsidiary of the Company with and into the Company by way of a scheme of arrangement. (As Per BSE Announcement Dated on:13.02.2026) | ||
| Board Meeting | 13 Nov 2025 | 23 Oct 2025 |
| Alkem Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2025 ,inter alia, to consider and approve the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and half year ended 30th September, 2025. Pls find enclosed the Outcome of Board Meeting dated 13.11.2025. Kindly take the same on record. (As per BSE Announcement dated on: 13.11.2025) | ||
| Board Meeting | 12 Aug 2025 | 4 Aug 2025 |
| Alkem Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2025 inter alia to consider and approve the Standalone and Consolidated unaudited Financial Results of the Company for the quarter ended 30th June 2025. Kindly take note of the same. Please find enclosed herewith outcome of the BM dated 12th Aug, 25. The meeting of BOD started at 11 am and concluded at 1.25 pm. (As Per BSE Announcement Dated on: 12/08/2025) | ||
| Board Meeting | 29 May 2025 | 16 May 2025 |
| Alkem Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2025 inter alia to consider and approve (i) the Standalone and Consolidated Audited Financial Results of the Company for the quarter and financial year ended 31st March 2025; and (ii) to consider and recommend Final Dividend if any for financial year ended 31st March 2025. Kindly take note of the same. Please find enclosed herewith the Outcome of Board Meeting dated 29th May, 2025. The meeting of the Board of Directors of the Company commenced at 11.25 a.m. and concluded at 13.45 p.m. Kindly take the same on record. Appt of M/s. Manish Ghia & associates, PCS as secretarial auditors for a term of 5 years w.ef 1st April 25 upto 31st march 2030 subject to approval of shareholders at the ensuing AGM (As Per BSE Announcement Dated on :29.05.2025) | ||
This inspection, conducted from March 10 through March 13, 2025, was to evaluate compliance with the legal standards concerning bioequivalence studies.
The company saw its revenues increase by 1.5% YoY at ₹3,374 crore from ₹3,324 crore.
The serum contains liposomal azelaic acid, liposomal 4-butyl resorcinol, tranexamic acid, alpha arbutin, and niacinamide.
R&D expenses rose to ₹146.5 crore, making up 4.3% of total revenue, compared to ₹115.8 crore (3.4% of revenue) in the previous year.
This comes after competing private equity firms TPG Capital, Apax Partners, and KKR withdrew their original interest.
Alkem will conduct clinical trials of 'SON-080' in India, with Sonnet's support for global and local regulatory submissions.
According to sources, the floor price would be ₹5,616 per share, which is 3% lower than the current market price (CMP).
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
